Learn how you can get involved to support clinical trials for patients with diffuse cutaneous systemic sclerosis (dcSSc)
About the Research Study
Novartis is currently conducting a phase 2 research study called VENUSS (CVAY736S12201), which is enrolling participants with diffuse cutaneous systemic sclerosis (dcSSc). The study is evaluating the efficacy, safety, and tolerability of the subcutaneous investigational drug, ianalumab, administered in dcSSc patients compared to placebo.
The investigational drug ianalumab, targets B cells, which are part of the immune system involved in causing dcSSc. By reducing the activity of B cells, researchers hope that the investigational drug may help improve symptoms of dcSSc.
For more information about the study, visit: https://clinicaltrials.gov/study/NCT06470048
How You Can Get Involved
As a health care provider (HCP) who manages patients with dcSSc, you are invited to participate in the Effectus Patient Identification and Consultation Program to help identify candidates for the VENUSS (CVAY736S12201) Study. Should you decide to participate, you would identify which of your adult patients meet the provided inclusion/exclusion criteria and discuss with them the opportunity to participate at the nearby study site. Patients will undergo formal study screening with the Principal Investigator to determine eligibility. Patients may be able to take part if they meet the following criteria*:
- Are 18 to 70 years of age
- Have had scleroderma skin lesions for no more than 5 years
*Patients will need to meet additional study criteria, which will be provided to you upon program training.
Compensation at fair market value will be provided to HCPs who participate and meet program requirements.
Effectus Patient Identification and Consultation Program Overview
Support Provided
Effectus will be your trusted partner throughout your participation, helping to facilitate your patients throughout the screening process and thus relieving the burden on your practice. If you wish to participate, you will be asked to review and sign a Services Agreement with Effectus, which outlines your program responsibilities and compensation. Participation is completely voluntary, and you can opt out at any time. Background on the study, program materials, and program logistics will be reviewed in detail during a 1-hour virtual training session, for which you will be compensated.
Why Participate?
There is currently no approved treatment that has been shown to slow or stop dcSSc from worsening. Participation in the Effectus Patient Identification and Consultation Program provides an opportunity for you to contribute to this research and advancement of a potential treatment for dcSSc.
Sign a services
agreement.
Receive a package of
program materials and
complete a simple, 1-hour
virtual training session.
Utilize key screening
criteria to identify
potentially eligible
patients.
If the patient meets the criteria,
conduct a neutral consultation
about the availability of the
nearby study and gauge the
patient’s interest.
If the patient is interested in
participation, our team of dedicated
Patient Facilitators help ensure a
smooth patient transfer from your
office to the study site.
The patient’s enrollment
status is determined and is
relayed back to the treating
HCP by Effectus.
For more information on our program, please visit https://www.effectusctr.com/physician-network/.
The Effectus Patient Identification and Consultation Program
Contact Us
Montana Ward, Project Manager
Phone: 973-753-2430
Email: mward@effectusctr.com